Answers are grounded in this paper and cite their sources.
Poorly validated antibodies generate misleading results and waste research resources. Two new studies in PLOS Biology quantify the ethical costs of this issue, examine why unvalidated antibodies are still used, and identify solutions to reduce their use.
No takes yet. Share an insight, caveat, or question.
Johan Duchêne (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: